Published in Hepatitis Weekly, May 15th, 2006
According to the report from the United States, "In May 2001, the U.S. Food and Drug Administration (FDA) approved Hepatitis A Inactivated and Hepatitis B Recombinant Vaccine (HEPAB) for immunization of adults. From May 2001 to September 2003, the Vaccine Adverse Event Reporting System (VAERS) received 305 reports of adverse events after HEPAB."
"Many events were similar to those reported after the monovalent hepatitis A and B vaccines," said Emily Jane Woo and colleagues at the U.S. Food and Drug Administration. "Non-serious events...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.